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Increased systemic and pulmonary levels of interleukin
(IL)-6 have been associated with the severity of acute
exacerbations and accelerated decline of lung function in
COPD patients. The demonstration that IL-6 plays a pivo-
tal role in AE-related pulmonary symptoms and therefore
represents a therapeutic target for the treatment of COPD,
remains elusive. We used a murine model where C57BL/6
female mice are exposed to cigarette smoke (CS) twice
daily through a nose-only system, while being punctually
challenged intranasally with poly I:C, a synthetic ligand for
Toll Like Receptor-3 (TLR3). This protocol recapitulates
several aspects of pulmonary inflammation as seen in
acute exacerbations of COPD, including prominent airway
neutrophilia as well as increased levels of type I interferon,
GM-CSF, IL-6, KC, MIP-1 alpha, RANTES, and TNF-
alpha in bronchoalveolar lavage (BAL) samples. Using this
model, IL-6 deficient mice showed a susceptibility to CS-
induced pulmonary inflammation that, overall, was com-
parable to that found with wild-type (WT) control mice.
In contrast, using the same model with WT mice treated
intraperitoneally with IL-6 neutralizing antibodies (rat
IgG1, clone MP5-20F3, 25 mg/kg thrice weekly) dimin-
ished blood counts of lymphocytes (p=0.0070) and mono-
cytes (p = 0.0091), while this treatment also depleted BAL
levels of IL-6 (p = 0.0002) and reduced BAL levels of KC
(p = 0.0220). Total BAL cellularity was found to be largely
decreased (p < 0.0001) as well as BAL numbers of neutro-
phils (p = 0.0031), lymphocytes (p < 0.0001) and macro-
phages (p < 0.0001), while inflammatory infiltrates seemed
reduced in lung tissue sections from treated mice. Our
results show that the neutralization of IL-6 largely abro-
gates pulmonary inflammation in CS-exposed mice, and
therefore indicate that IL-6 may be a valid therapeutic tar-
get for the treatment of COPD, in particular in episodes of
acute exacerbation.
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